# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jack London (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET010-SYN-TD
- Date: 1915-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe-Ibe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Twelve-week review. **S**

## History of present illness

Mr. London has had no alcohol for eight weeks. He has taken dapagliflozin for two weeks with a little more passing of urine and no dizziness, genital symptoms or illness, and has not needed the sick-day rules. He takes losartan 100 mg, naltrexone, thiamine and vitamin D3 every morning. His home readings average 120/76. He writes every morning and has started a new novel; he swims or rides in the late morning. He would like to stop smoking in the new year. He asks what the next months hold for his kidneys. **S**

| Element | Detail |
|---|---|
| Alcohol | None for eight weeks; PEth 6 ng/mL; AUDIT 9 for the past three months |
| Kidneys | Creatinine 2.13 mg/dL, eGFR 40 after two weeks of dapagliflozin; potassium 4.7; urine albumin 96 mg/g |
| Liver tests | AST 29, ALT 26, GGT 54 U/L; MCV 96 fL |
| Mood | PHQ-9 4, item 9 scored 0; GAD-7 4 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight down 3.3 kg since intake |
| Genitourinary | Positive | Passing a little more urine; no burning, itching or discharge |
| Cardiovascular | Negative | No dizziness on standing; no ankle swelling |
| Psychiatric | Negative | Mood good; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Losartan 100 mg oral tablet once daily **S**
- Thiamine 100 mg oral tablet once daily **S**
- Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen **S**
- Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicines **S**
- Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily **S**
- Dapagliflozin 10 mg oral tablet once daily, held on any day he cannot eat or drink normally, and before surgery **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 80.9 kg; BMI 27 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.7 mmol/L; Bicarbonate (total CO2): 23 mmol/L; Urea nitrogen: 24 mg/dL (high); Creatinine: 2.13 mg/dL (high); eGFR (CKD-EPI 1910): 40 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 96 mg/g (high); AST: 29 U/L; ALT: 26 U/L; GGT: 54 U/L; MCV: 96 fL; PEth (alcohol marker): 6 ng/mL; AUDIT: 9; PHQ-9: 4; GAD-7: 4. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.6 mmol/L at baseline, 4.7 mmol/L at this visit **S**
- Bicarbonate (total CO2): 22 mmol/L at baseline, 23 mmol/L at this visit **S**
- Urea nitrogen: 28 mg/dL (high) at baseline, 24 mg/dL (high) at this visit **S**
- Creatinine: 1.98 mg/dL (high) at baseline, 2.13 mg/dL (high) at this visit **S**
- eGFR (CKD-EPI 1910): 43 mL/min/1.73 m² (low) at baseline, 40 mL/min/1.73 m² (low) at this visit **S**
- Urine albumin-to-creatinine ratio: 240 mg/g (high) at baseline, 96 mg/g (high) at this visit **S**
- AST: 68 U/L (high) at baseline, 29 U/L at this visit **S**
- ALT: 41 U/L at baseline, 26 U/L at this visit **S**
- GGT: 186 U/L (high) at baseline, 54 U/L at this visit **S**
- MCV: 101 fL (high) at baseline, 96 fL at this visit **S**
- PEth (alcohol marker): 410 ng/mL (high) at baseline, 6 ng/mL at this visit **S**
- AUDIT: 27 at baseline, 9 at this visit **S**
- PHQ-9: 9 at baseline, 4 at this visit **S**
- GAD-7: 7 at baseline, 4 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), second of two doses **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/78, pulse 70; weight 80.9 kg, BMI 27.0 |
| Cardiovascular | Regular rhythm; no edema; no fall in blood pressure on standing |
| Abdomen | Soft; liver edge not felt |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3b A2** (N18.32). eGFR 40, from 44, two weeks after dapagliflozin: the expected early dip of about 9 percent, well within the 30 percent accepted; potassium 4.7 mmol/L. Urine albumin 96 mg/g, down 60 percent from 240. Stage G3b A2. **S**
   - Continue losartan 100 mg and dapagliflozin 10 mg.
   - Creatinine, eGFR, urine albumin and potassium in three months, then twice a year; calcium, phosphate and PTH in six months.
   - Nephrology review in three weeks, three months after the consultation.
2. **Hypertensive chronic kidney disease** (I12.9). 122/78 by standardized measurement, close to a systolic target below 120. **S**
   - If systolic stays above 120 at three months, add amlodipine 5 mg.
3. **Alcohol use disorder, severe, in early recovery (early remission needs three months without criteria)** (F10.20). Eight weeks abstinent with PEth 6 ng/mL; liver tests and MCV normal. AUDIT 9 for the past three months. Safety reviewed: no thoughts of suicide or self-harm, firearms locked, 988 card carried. **S**
   - Continue naltrexone for at least a year.
   - Counseling every two weeks from now.
   - PEth every two to three months.
4. **Cigarette smoking** (F17.210). Ready to set a quit date in the new year. **S**
   - Nicotine patch with a short-acting form, or varenicline, at the next visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated device, average of readings) | Every visit | Completed today | 122/78 mmHg; home average 120/76 |
| Laboratory | Potassium and creatinine after starting or changing losartan or an SGLT2 inhibitor | Two to four weeks after each start or change | Completed today | Two weeks after dapagliflozin: potassium 4.7 mmol/L; creatinine 2.13 mg/dL, an expected 9 percent fall in eGFR |
| Laboratory | Creatinine with eGFR and urine albumin-to-creatinine ratio | G3b A2: twice a year, and at each medicine check | Completed today | eGFR 40; urine albumin 96 mg/g |
| Laboratory | Electrolytes and bicarbonate | With each kidney test | Completed today | Sodium 139; bicarbonate 23; urea nitrogen 24 mg/dL |
| Laboratory | Calcium, phosphate and PTH | G3a to G3b: every six to twelve months | Up to date | Due in six months |
| Medication safety | SGLT2 inhibitor safety: sick-day rules, ketoacidosis, genital infection, volume | Every visit | Completed today | No genital infection, dizziness or illness; sick-day rules understood |
| Medication safety | Medication reconciliation: no NSAIDs, kidney dosing, contrast safety | Every visit | Completed today | No NSAIDs; all doses checked for his eGFR |
| Self-management | Lifestyle: sodium below 2 g a day, activity, diet, weight | Every visit | Completed today | Less salt; swims or rides most days; 3.3 kg lost |
| Self-management | Vaccination review (pneumococcal, influenza, hepatitis B, COVID-19) | Yearly | Completed today | Second hepatitis B dose today; influenza, PCV20 and hepatitis A given at the preventive visit |
| Survey | Drinking since the last visit (self-report) | Every visit | Completed today | None for eight weeks |
| Laboratory | PEth | At baseline and every four to six weeks in early recovery | Completed today | 6 ng/mL: abstinence |
| Survey | AUDIT | At intake and at three months | Completed today | 9 for the past three months, from 27 |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | At baseline, at four to six weeks, then every few months | Completed today | AST 29, ALT 26, GGT 54 U/L; MCV 96 fL |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | Every visit | Completed today | No nausea; no opioid |
| Referral | Addiction-focused counseling and mutual help | Weekly in early recovery, then every two weeks | Completed today | Ten sessions; every two weeks from now |
| Survey | PHQ-9 and GAD-7 | At intake and at follow-up | Completed today | PHQ-9 4 with item 9 scored 0; GAD-7 4 |
| Survey | Suicide-risk review, firearms storage, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms locked; 988 card carried |
| Self-management | Tobacco use and readiness to stop | Every visit | Completed today | Ready to set a quit date |

## Goal progress

- Find out how much kidney function is lost, how long it has been so, and why. Outcome by 1915-08-18: Chronic kidney disease G3b A2 from hypertension with naproxen contributing; no stones, obstruction or glomerular disease suspected. **S**
- Stop drinking safely, and stay stopped. In progress; target 1916-02-02. **S**
- Blood pressure below 120 systolic by standardized office measurement if tolerated, and at least below 130/80. In progress; target 1916-02-02. **S**
- Urine albumin down by at least 30 percent. Outcome by 1915-10-27: 240 to 96 mg/g on losartan and then dapagliflozin. **S**
- No anti-inflammatory pain medicines, and pain controlled. Outcome by 1915-10-27: No naproxen since intake; acetaminophen and topical treatment only, including for an ankle sprain. **S**
- Keep the morning writing hours. Outcome by 1915-10-27: Wrote every morning through the twelve weeks except the two days of the worst withdrawal. **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026), Aether Forge
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force

## Follow-up

- Nephrology review in three weeks. Primary care in three months with creatinine, eGFR, urine albumin, potassium and PEth. Counseling every two weeks. The clinic or 988 at any hour. **S**

